PDC*line Pharma presents interim clinical results from last cohort of patients in phase I/II trial with PDC*lung01 cancer vaccine menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Intermediary results of high dose PDC lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and.
LIÈGE, Belgium & GRENOBLE, France, April 08, 2024 PDC line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC lung01.
PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in PDC-LUNG-101 Phase I/II Clinical Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
E-Mail
Lugano, Switzerland; Denver, CO, USA, 12 March 2021 - The European Lung Cancer Congress 2021, the annual event devoted to advance the quality of lung cancer treatment, will be held as a virtual meeting (25-27 March). (1)
More than 200 studies will be presented (oral or e-poster presentations) and published online as a supplement of the Journal of Thoracic Oncology. (2)
Programme highlights
New perspectives in the treatment of small cell lung cancer and mesothelioma, including novel agents and prospects for chemotherapy, radiotherapy and immunotherapy
Lung cancer prevention, with a focus on smoking cessation and the safety and effectiveness of e-cigarettes
Management and treatment options for both early and advanced stage disease in non-small cell lung cancer